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Abstract
Background: Von Willebrand factor (VWF) is critical for the in vivo survival of factor VIII (FVIII). Since FVIII half-life correlates
with VWF-antigen pre-infusion levels, we hypothesized that VWF levels are useful to predict FVIII half-life.
Methodology: Standardized half-life studies and analysis of pre-infusion VWF and VWF-propeptide levels were performed in
a cohort of 38 patients with severe haemophilia A (FVIII ,1 IU/ml), aged 15–44 years. Nineteen patients had blood-group O.
Using multivariate linear regression-analysis (MVLR-analysis), the association of VWF-antigen, VWF-propeptide, age and
body-weight with FVIII half-life was evaluated.
Principal Findings: FVIII half-life was shorter in blood-group O-patients compared to non-O-patients (11.562.6 h versus
14.363.0 h; p=0.004). VWF-antigen levels correlated with FVIII half-life considerably better in patients with blood-group
non-O than O (Pearson-rank=0.70 and 0.47, respectively). Separate prediction models evolved from MVLR-analysis for
blood-group O and non-O patients, based on VWF-antigen and VWF/propeptide ratio. Predicted half-lives deviated less than
3 h of observed half-life in 34/38 patients (89%) or less than 20% in 31/38 patients (82%).
Conclusion: Our approach may identify patients with shorter FVIII half-lives, and adapt treatment protocols when half-life
studies are unavailable. In addition, our data indicate that survival of FVIII is determined by survival of endogenous VWF
rather than VWF levels per se.
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Introduction
The bleeding disorder haemophilia A is caused by defects in the
gene encoding coagulation factor VIII and affects 1–2 in 10,000
male births [1]. In plasma, FVIII circulates in a tight non-covalent
complex with von Willebrand factor (VWF). The formation of this
complex is of physiological importance to maintain appropriate
plasma levels of FVIII [2,3]. Indeed, patients lacking VWF (von
Willebrand disease (VWD) type 3)) not only have a secondary
deficiency of FVIII, but also a strongly reduced half-life of
intravenously administered FVIII [4].
Current treatment of patients with severe haemophilia A (FVIII
,1 IU/ml) mainly involves replacement therapy using purified
plasma-derived or recombinant FVIII. Since the early 1970s,
treatment protocols started to shift from on-demand replacement-
therapy in cases of bleeds, towards prophylactic treatment to
prevent bleeds. Initially, this was applied for patients who had
already experienced several joint bleeds [5]. More recently,
prophylactic treatment is administered more stringently and is
often started before the onset of joint damage and after no more
than 1 or 2 joint bleeds. Although prophylactic treatment has been
proven to be beneficial for the patient, it requires regular infusions
(up to 3 times per week) because of the relative short half-life of
FVIII. The average half-life of FVIII in adult haemophilia A
patients is 12 h, but a large variation between individuals (6–29 h)
has been observed [6,7]. Individualization of prophylactic
treatment according to half-life may help optimizing treatment-
protocols and improve efficiency of FVIII use. This is of particular
relevance in children on prophylaxis, since bleeding is determined
by time spent below 1% FVIII activity levels [8]. Also, information
on FVIII half-life might be needed during a perioperative period
of replacement-therapy in both children and adults, to determine
the optimal interval between FVIII infusions and/or dosing during
continuous infusion. However, individual half-life studies requiring
frequent venipunctures during 72 h are time-consuming and
difficult to perform especially in children [8].
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variation in half-life. Of these, VWF levels appear most relevant: a
correlation between pre-infusion VWF levels and FVIII half-life has
been described in at least two separate studies [6,9]. Since VWF
levels are on average 25% lower in blood group O individuals
compared to blood group non-O individuals, it is therefore not
surprising that FVIII half-life is shorter in haemophiliacs with
blood-group O than in those with other blood-groups [9,10].
Recently, we have described a cohort of 38 severe haemophilia
A patients, in whom FVIII half-life has been determined [7]. We
have re-analyzed these data in order to investigate which
parameters can be used to predict FVIII half-life in these patients
with reasonable accuracy. In addition to VWF-antigen, we also
considered VWF-propeptide (which is secreted simultaneously
with mature VWF in a 1:1 ratio) [11], the VWF/propeptide ratio
(which provides information on the relative differences in
clearance rates between both proteins) [12,13], age and body-
weight (both of which are known to influence VWF levels) [14].
Materials and Methods
Patients
From the cohort treated at the Van Creveldkliniek, thirty-eight
patients with severe haemophilia A (FVIII activity ,0.01 IU/ml)
were included in the present analysis. All came from a cohort of 42
patients selected according to phenotype that has been described
elsewhere [7,15]. None of the patients were HIV-positive, had
liver failure, fever in the previous 48 h, elevated CRP, low
platelets, increased prothrombin time, low factor V, signs of liver
cirrhosis on ultrasound, severe bleeding or surgery in the previous
3 months, or antibodies against FVIII (as assessed by an
immunosorbent-assay and a Bethesta-assay (sensitivity 0.3
Bethesta Units/ml)). Mean age was 26.3 years (standard deviation
11.6, range 10.3–47.2). Four patients were excluded from the
present study, because no plasma material was available for
determination of VWF propeptide levels at the time of analysis,
leaving 38 patients for this study. Nineteen patients were blood-
group O, and nineteen were non-O (12 A, 5 B, 2 AB).
Study design
The present analysis was based on data from a previous study,
in which FVIII half-life was assessed in a standardized manner [7].
In short: patients had had no FVIII for at least 72 h before testing,
they received a dose of 50 IU/kg recombinant FVIII concentrate,
blood samples were taken at 15 min, 30 min and 1, 3, 5, 24, 30, 48
and 60 h after infusion. The pharmacokinetic program PK
solutions (Summit Research Services, Montrose, CO) was used
to calculate FVIII half-life using model-independent calculations,
as recommended elsewhere [16].
Laboratory assays
VWF-antigen and VWF-propeptide antigen levels were deter-
mined and values were converted into molar concentrations as
described [11,17,18]. Antigen levels were determined indepen-
dently, without knowledge of corresponding FVIII half-life values
in order to improve internal validity.
FVIII survival studies in FVIII-deficient mice
FVIII-deficient mice (mixed C57Bl6/J-129 Sv background with
a deletion in exon 16, obtained from The Jackson Laboratory, Bar
Harbor, ME) were between 8 and 10 weeks of age. Mice were
treated with recombinant interleukin-11 (rIL-11, obtained from
ProSpec, Rehovot, Israel) to raise VWF levels or vehicle as
described previously [19]. Briefly, blood was first collected 3 days
before injections started to determine base-line values. To this end,
mice were anaesthetized using isoflurane, and blood was obtained
via retro-orbital puncture. Two drops of blood were collected in
EDTA (5 mM) for blood counts and 200 microliters were collected
in citrate for VWF antigen determination. Subsequently, mice
were injected subcutaneously with vehicle or rIL-11 (250 mg/kg)
for 7 consecutive days. On day 8, mice were injected intravenously
via the tail-vein with recombinant VWF-free FVIII (Kogenate,
150 U/kg). At indicated timepoints (3 min, 15 min, 30 min or
1 h), mice were anaesthetized using tribromoethanol (0.15 ml per
10 g of body weight). Blood was collected in a similar fashion (2
drops in EDTA for blood count and 200 microliters in citrate for
VWF antigen and FVIII activity). VWF antigen and FVIII activity
were determined as described previously [20,21]. For each time-
point three mice were used in each group.
Ethics statement
All patients and/or parents gave written informed consent for
the sampling of blood for scientific purposes, per the Declaration
of Helsinki. Approval was obtained from the institutional review
board of the University Medical Center Utrecht (Utrecht, the
Netherlands). Animal housing and experiments were done as
recommended by French regulations and according to experi-
mental guidelines of the European Community.
Data analysis
First, Pearson correlations for FVIII half-life with VWF-antigen,
VWF-propeptide, VWF/propeptide ratios, age and body-weight
were determined. Subsequently, stepwise-backwards multivariate
linear regression (MVLR)-analysis was used to assess the
independent associations of these parameters with FVIII half-life
(SPSS 12.0 Inc, Chicago, IL). All parameters with a p-value of
0.15 or higher were excluded after each step. Separate analyses
were performed for blood-group O and non-O. The stepwise-
backwards procedure was used because all of the tested variables
represent parameters known to be associated with VWF
metabolism. To assess calibration of the models, FVIII half-lives
predicted by the model were compared to the observed half-life for
each patient. Absolute and proportional deviations from observed
half-lives were calculated. Data are presented as mean6SD unless
stated otherwise. P-values of less than 0.05 were considered
statistically significant.
Results
FVIII half-life in blood-group O and non-O haemophilia A
patients
The FVIII half-life in this cohort of 38 severe haemophilia A
patients varied between 7.4 and 20.4 h, with a mean half-life of
12.963.1 h (mean6S.D.) [7]. Patient characteristics and test
results according to blood-group are summarized in Table 1. As
expected, average FVIII half-life was significantly shorter in blood-
group O patients than in non-O patients (11.562.6 h versus
14.363.0 h). Furthermore, average VWF levels were lower in
blood-group O patients than in non-O patients (36.267.0 nM
versus 51.1622.2 nM). In contrast, propeptide levels were similar
for both groups (4.761.0 nM versus 5.061.6 nM). As a conse-
quence, VWF/propeptide ratios were significantly increased in
blood-group non-O patients compared to O patients (10.362.5
versus 7.861.5).
Pre-infusion VWF-antigen levels and FVIII half-life
In view of the previously reported correlation between VWF
pre-infusion levels and FVIII half-life [6], it was of relevance to
Predicting FVIII Half-Life
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significant correlation between pre-infusion VWF-antigen levels
and FVIII half-life was observed in blood-group non-O patients
(Pearson-rank=0.70; p=0.001; Fig. 1A). However, this correla-
tion appeared to be less obvious in O-patients, although it still
reached statistical significance (Pearson-rank=0.47; p=0.044;
Fig. 1B). Given these blood-group dependent differences, the
association between the various parameters and FVIII-half-life was
evaluated separately for blood-group O and other patients.
Univariate regression-analysis of parameters potentially
useful for prediction of FVIII half-life
In search for additional valuable parameters to predict FVIII
half-life, we considered a number of alternatives besides VWF-
antigen: (1) VWF-propeptide, which is secreted in a 1:1 molar ratio
with VWF. In contrast to mature VWF, VWF-propeptide is devoid
of ABO-glycan determinants [12]; (2) VWF/propeptide ratio. Due
to differences in half-life of mature VWF and VWF-propeptide, a
distinct VWF ratio is present under steady-state conditions [13]. A
more or less pronounced clearance of VWF compared to its
propeptide will become apparent via this ratio; (3) Age and body-
weight, both of which may influence VWF-antigen levels [14].
In a first approach, Pearson correlations for each separate
parameter were determined, the results of which are summa-
rized in Tables 2 and 3. For blood-group non-O, a strong
correlation with FVIII half-life was observed for VWF propeptide
(Pearson-rank=0.76; p=0.001), which appeared to be slightly
better compared to VWF-antigen. A weaker correlation was
observed for age (Pearson-rank=0.50; p=0.028). For blood-group
O patients, a strong correlation with FVIII half-life was observed
for VWF/propeptide ratio only (Pearson-rank=0.70; p=0.001),
which was considerably stronger than the correlation found for
VWF-antigen.
Stepwise-backwards MVLR-analysis
In a subsequent step, data were analyzed via stepwise-
backwards MVLR-analysis to assess interdependence of these
parameters. In each step, each parameter having a p-value of more
than 0.15 was eliminated. Using this approach, age, weight and
propeptide were eliminated as predictive parameters while
analyzing blood-group non-O patients. The remaining parameters
(VWF-antigen and VWF/propeptide ratio) were used to define the
following predictive equation, which explained 57% of all
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For blood-group O patients, the sole predictive parameter that
remained following stepwise-backwards MVLR-analysis was the
VWF/propeptide ratio, resulting in predictive equation 2.
Figure 1. Relation between FVIII half-life and pre-infusion VWF-antigen levels. Panels show the correlation between FVIII half-life and VWF
pre-infusion levels in severe haemophiliacs with blood-group non-O (panel A) and blood-group O (panel B). Drawn lines represent best-fit obtained
after univariate linear regression.
doi:10.1371/journal.pone.0006745.g001
Table 1. Patient characteristics according to blood-group.
Blood-group non-O Blood-group O p-value
N=19 N=19
Age (y) 28.1610.0 27.5613.6 0.88
Body-weight (kg) 75.8618.4 67.1618.4 0.15
FVIII half-life (h) 14.363.0 11.562.6 ,0.01
VWF-antigen (nM) 51.1622.2 36.267.0 ,0.01
VWF-propeptide antigen (nM) 5.061.6 4.761.0 0.61
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Model performance of MVLR-analysis according to blood-group is
shown in Tables 4 and 5. The median deviation was +0.30 h (95% CI
from 20.87 to +0.93) for blood-group non-O patients and +0.40 h
(95% CI from 20.92 to +0.87) in patients with blood-group O. Thus,
there is a slight tendency to overestimate FVIII half-life using these
predictive equations. Nevertheless, the overall predicted half-life was
within 3 h difference of the observed half-life in 34 of 38 patients
(89%), when comparing predicted and observed half-lives. The
proportional difference was within 20% in 31 of 38 patients (82%).
When analyzing the distribution of half-lives in our cohort, it
appeared that the majority of the patients (27 of 38, i.e. 71.0%)
displayed half-lives between 10 and 14 h. Only 2 patients (5.3%) had a
half-life of less than 10 h, whereas 9 patients (23.7%) had a FVIII half-
life longer than 14 h. To test whether our model would be useful to
identify patients that have half-lives outside the range of 10–14 h, we
examined how many patients where correctly placed in either of the
three groups (,10, 10–14, .14 h). We found that 31 of 38 patients
(82%) were correctly grouped in each of the three groups after
applying our model. Of the 7 wrongly grouped patients, 3 patients
were predicted to have a half-life .14 h, whereas their observed half-
life was 10–14 h. Three other patients had a FVIII half-life .14 h,
but where predicted to be in the 10–14 h group. One patient with an
observed half-life of 10 h was predicted to have a half-life of 9 h.
Effect of raising VWF levels in vivo on FVIII survival
Given the strong relationship between VWF pre-infusion levels
and FVIII half-life, it was of interest to investigate whether
manipulation of VWF levels is a useful tool to influence FVIII
survival. Two potential mechanisms may explain this strong
relationship. First, individual VWF levels are determined by its
clearance rate, in which low clearance is associated with increased
VWF levels. In this scenario, FVIII would survive longer in the
circulation in these individuals, since its carrier-protein VWF has a
low clearance rate. Second, a larger excess of VWF over FVIII
may force unbound FVIII molecules (normally estimated to
encompass 2–5% of the FVIII molecules [22,23]) into complex
with VWF, thereby reducing the amount of free FVIII which is
cleared more rapidly than VWF-bound FVIII. To investigate
whether increasing VWF levels within the physiological range is
sufficient to increase the survival of FVIII, we made use of the
previous observation that treatment with rIL-11 is associated with
an increase in VWF levels without affecting its half-life [19,24,25].
Therefore, FVIII-deficient mice were injected subcutaneously with
rIL-11 (0.25 mg/kg) once a day for 7 consecutive days [19]. As
expected, an increase in platelet count was observed for rIL-11-
treated mice (478659 10
3 platelets/ml and 708681 10
3 platelets/
ml, before and after treatment; mean6S.D.) but not for placebo-
treated mice (472690 10
3 platelets/ml and 4836144 10
3 plate-
lets/ml, before and after treatment). Also VWF levels were
increased upon rIL-11 treatment, resulting in levels that were
1.7-fold higher in rIL-11-treated FVIII-null mice compared to
placebo-treated FVIII-null mice. At day 8, both rIL-11-treated and
placebo-treated mice were injected intravenously with recombi-
nant FVIII (150 U/kg) and blood was collected up to 1 h after
injection (3 mice per time-point for each group) to determine
FVIII survival. Analysis of FVIII activity in plasma samples
revealed no difference in residual FVIII activity at any of the time-
points tested (up to 1 hour after injection; see supplementary
Figure S1). Thus, increasing steady-state VWF levels was not
associated with an increased survival of FVIII in this mouse model.
Discussion
It has been recognized since long that survival of intravenously
administered FVIII varies greatly between haemophilia A patients.
Individual half-life studies could therefore be used to optimize
individual treatment protocols. Such studies often require multiple
blood samplings over a period of several days. In order to simplify
the issue of FVIII half-life determination, the current study
presents blood-group specific prediction models based on the
analysis of a cohort of 38 haemophilia A patients. This cohort
consists of 19 patients having blood-group O and 19 patients
having blood-group non-O. Since FVIII half-life differed signif-
icantly between both patient-groups (11.562.6 h versus
14.363.0 h, respectively), we decided to analyze both groups
separately.
It has previously been reported that VWF pre-infusion levels
correlate to some extent with FVIII half-life [6,9], which was
confirmed in our study. In order to build a prediction model, we
also considered a number of parameters that are related to the
metabolism of VWF. Via stepwise-backwards MVLR-analysis,
only two parameters appeared to be of relevance with regard to
their predictive value of FVIII half-life: VWF-antigen (for blood-
group non-O patients) and VWF/propeptide ratio (for patients of
both blood-groups). Using these parameters, FVIII half-life could
be predicted with a deviation of maximal 3 h of the observed half-
life in 34/38 patients (89%). This is a considerable improvement
compared to the use of VWF antigen levels as a predictive
parameter, which results in a deviation of maximal 3 h in 22/38
patients (58%). In addition, our analysis allowed us to identify
those patients that have half-lives that are outside the normal




coefficient 95% CI p-value
Age (y) 0.15 0.02 to 0.29 0.03
Body-weight (kg) 0.02 20.06 to 0.11 0.56
VWF-antigen (nM) 0.10 0.05 to 0.14 ,0.01
VWF-propeptide antigen (nM) 1.41 0.80 to 2.02 ,0.01
VWF/propeptide ratio 0.28 20.33 to 0.89 0.34
doi:10.1371/journal.pone.0006745.t002




coefficient 95% CI p-value
Age (y) 0.04 20.06 to 0.14 0.42
Body-weight (kg) 0.03 20.04 to 0.10 0.41
VWF-antigen (nM) 0.18 0.01 to 0.34 0.04
VWF-propeptide antigen (nM) 20.54 21.92 to 0.83 0.42
VWF/propeptide ratio 1.19 0.57 to 1.82 ,0.01
doi:10.1371/journal.pone.0006745.t003
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than 14 h) with an accuracy of .80%.
The finding that the inclusion of VWF-antigen levels in liaison
with VWF/propeptide ratio was required for optimal prediction of
FVIII half-life in non-O patients but not in blood-group O patients
is intriguing. One potential explanation could originate from the
larger variability in VWF-antigen levels in blood-group non-O
patients (ranging from 23 to 101 nM) compared to blood-group O
patients (ranging from 19 to 47 nM). Since VWF and its
propeptide are secreted in a coordinated manner, the variability
in VWF levels may be compensated via inclusion of propeptide
levels. Indeed, the range in propeptide levels was merely
overlapping in both patient groups (2.7–8.5 nM and 3.4–7.3 nM
for patients with blood-group non-O and O, respectively).
Irrespective of the differences in the equations that describe the
correlation with FVIII half-life between both patient groups
(blood-group non-O versus O), we would like to emphasize that
our observations are of an empirical character. Nevertheless, we
feel that our approach has resulted in a simple method that allows
prediction of FVIII half-life with reasonable accuracy and
identification of patients with shorter half-lives. This approach
may facilitate the design of dosing strategies for haemophilia A
patients in the absence of individual half-life studies. It should be
noted that our current study lacks a true verification of our model,
since no second independent dataset has been tested. Additional
studies are therefore needed to validate and, eventually to refine
our findings.
Does the finding that increased VWF levels positively associate
with FVIII half-life allows the conclusion that the survival of FVIII
may be prolonged by artificially increasing endogenous VWF
levels? This would be true if the effect of VWF is independent of
the rate by which endogenous VWF is cleared from the
circulation. Rather it should rely on the molar excess of VWF
over FVIII, which theoretically would result in more FVIII being
forced into complex formation with VWF. We have tested this
possibility in an experimental mouse model, in which we used rIL-
11 to increase steady-state levels of VWF over a prolonged period
of time. However, FVIII administered to these mice displayed
similar survival as FVIII injected in vehicle-treated control mice.
The possibility exists that the lack of effect on FVIII half-life is
because VWF levels were outside the range of correlation between
VWF levels and FVIII half-life. However, VWF levels were
increased in rIL-11 treated mice from 100% to 170%. This
concentration is well within the range of correlation observed in
our cohort, where VWF levels varied between 40% and 220% of
normal. An alternative explanation could relate to the extent of
VWF,FVII complex formation, in that our system is too
insensitive to detect the effect of a minor increase in complex
formation on FVIII half-life. It can be calculated that an increase
of 95% complex formation to 98% complex formation theoret-
ically results in a 2.5–3% slower clearance of the FVIII molecule
per 10 min in our mouse model (assuming mean residence time of
10 min for free FVIII and 150 min for VWF-bound FVIII). Over
the 60-min period that we monitored, the accumulative difference
in clearance should have been detectable in our experimental
model. Since this was not observed, the extent in increase in VWF
levels in our model is apparently too small to influence complex
formation so that FVIII survival is affected.
The effect of increasing pre-infusion VWF levels on FVIII half-
life has also been examined in human patients. One way to
increase VWF levels is via treatment using desmopressin [26,27].
Previously, two reports describing the effect of desmopressin-
treatment on FVIII survival have been published. First, a study
Figure 2. Calculated FVIII half-life versus observed FVIII half-life. Calculated FVIII half-lives were obtained using equations 1 or 2 (Panels A
and B, respectively), using pre-infusion VWF and propeptide levels, and are plotted versus observed FVIII half-lives of blood-group non-O (panel A)
and blood-group O patients (panel B). Solid lines represent ideal correlation between calculated and observed half-lives, while dotted lines indicate
20% deviation margins.
doi:10.1371/journal.pone.0006745.g002




coefficient 95% CI p-value
VWF-antigen (nM) 0.14 0.08 to 0.20 ,0.01
VWF/propeptide ratio 20.59 21.15 to 20.04 0.04
doi:10.1371/journal.pone.0006745.t004




coefficient 95% CI p-value
VWF/propeptide ratio 1.19 0.57 to 1.82 ,0.01
doi:10.1371/journal.pone.0006745.t005
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on FVIII survival upon treatment with desmopressin [28]. It
should be noted that this study dates from over 20 years ago. It
cannot be excluded that FVIII concentrates that were used in that
study contained large amounts of VWF and therefore any increase
in endogenous VWF may become less relevant. In a more recent
study, Deitcher and colleagues compared plasma-derived and
recombinant FVIII preparations that are essentially free of VWF
(i.e. Monoclate-P and Bioclate) [29]. They reported similar half-
lives for both preparations upon co-treatment with desmopressin.
A similar result (no increase in half-life) was also reported in a
preliminary study by Fijnvandraat and coworkers, in which a small
group of patients was treated with Aafact (a plasma-derived FVIII
therapeutic similar to Monoclate-P) in the presence or absence of
desmopressin [30]. Apparently, increasing VWF-antigen via
desmopressin- or rIL11-treatment is not helpful in prolonging
half-life of FVIII.
In conclusion, FVIII half-life after infusion with recombinant
FVIII concentrates in patients with severe haemophilia A is largely
dependent on blood group. For blood-group non-O patients,
FVIII half-life was best predicted by a model depending on both
VWF antigen levels and on VWF/propeptide ratio. For patients
with blood-group O, FVIII half-life was best predicted by VWF/
propeptide ratio. The importance of the VWF/propeptide ratio in
both models suggests that FVIII half-life is more dependent on the
rate of endogenous VWF clearance rather than on absolute VWF
levels. This possibility was supported by our mouse-model in
which VWF levels but not FVIII survival was increased using rIL-
11. The prediction-models presented may facilitate individualized
treatment according to pharmacokinetics in the absence of
individual half-life studies in haemophilia A patients.
Supporting Information
Figure S1 Factor VIII-deficient mice were treated with vehicle
or recombinant IL-11 for 7 consecutive days. VWF levels
remained unchanged in vehicle-treated mice, but were increased
1.7-fold in IL-11 treated mice. Mice were subsequently injected
intravenously with recombinant VWF-free FVIII (150 U/kg), and
blood samples were taken at indicated time-points. The graph
displays residual FVIII levels at indicated time-points for both
vehicle- and IL-11 treated mice. At none of the indicated time-
points, a statistical significant difference in residual FVIII activity
was detected. Data represent mean6SD of 3 mice per time-point.
Found at: doi:10.1371/journal.pone.0006745.s001 (0.03 MB
PDF)
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